Mylan, like other generic drugmakers, feels the pricing pain

FILE - This Oct. 10, 2013, file photo, shows an EpiPen epinephrine auto-injector, a Mylan product, in Hendersonville, Texas. Mylan reports earnings Wednesday, Aug. 9, 2017. (AP Photo/Mark Zaleski, File)

NEW YORK — Mylan's second-quarter profit and revenue surged, but not as much as Wall Street had expected and the company is taking a more conservative view going forward because of "ongoing challenges and the uncertain U.S. regulatory environment."

Shares tumbled 5 percent and were trading close to four-year lows at the opening bell Wednesday.

The generic drugmaker, which is incorporated in the United Kingdom but has its U.S. headquarters outside of Pittsburgh, said profit surged 76 percent to $297 million, or 55 cents per share.

Earnings, adjusted for non-recurring costs, came to $1.10 per share, well below the per-share estimates of $1.18 that Wall Street was seeking, according to a survey by Zacks Investment Research.

Revenue surged 15.6 percent to $2.96 billion on higher sales in Europe, largely due to products now owned by Mylan after its buyout of the Swedish drugmaker, Meda. However, that too was short of analyst expectations.

Mylan and its rivals that make generic drugs have been under pressure because of falling prices.

Mylan is also dealing with a decline in sales for its EpiPen Auto-Injector, following a decision to start selling a lower-priced generic version. That decision was made after the cost of the devices drew scorn from parents nationwide and spawned Congressional inquiries.

"Given the region's ongoing challenges and the uncertain U.S. regulatory environment, we have elected to defer all major U.S. launches from our full year 2017 financial guidance to 2018, including generic Advair and generic Copaxone," said CEO Heather Bresch. "As a result, we now expect to deliver total revenues this year of between $11.5 billion and $12.5 billion."

The previous projection from Mylan was for revenue of between $12.25 billion and $13.75 billion.

Per-share projections released Wednesday of between $4.30 and $4.70 are also down from earlier expectations of between $5.15 and $5.55.

The expectations for all of fiscal 2018 were also trimmed, from $6 a share, to $5.40 a share.

Citi analyst Liav Abraham said that Mylan's struggles mimic earlier quarterly reports from others in the generic industry.

"This morning's earnings, while consistent with the larger generic players thus far (TEVA and Sandoz in particular), are nonetheless not particularly reassuring, and point to structural issues in the US generics landscape," Abraham wrote.

Mylan shares have declined 17 percent since the beginning of the year.

_____

Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYL at https://www.zacks.com/ap/MYL

_____

Keywords: Mylan, Earnings Report

Must Read

Deutsche Bank says 'sorry' in full-page German newspaper ads

Feb 4, 2017

Deutsche Bank has apologized in full-page newspaper ads for misconduct that has cost the company billions

Eurozone chief hopes for movement on Greek debt talks

Jan 26, 2017

The eurozone's top official says he's hopeful that Greece and its creditors can advance talks on completing an important review of the country's bailout program

Declining sales force, revenue send Avon shares tumbling

Feb 16, 2017

Avon shares take a tumble after the company reports earnings and revenue that fall short of Wall Street expectations

People also read these

Deutsche Bank says 'sorry' in full-page German newspaper ads

Feb 4, 2017

Deutsche Bank has apologized in full-page newspaper ads for misconduct that has cost the company billions

Eurozone chief hopes for movement on Greek debt talks

Jan 26, 2017

The eurozone's top official says he's hopeful that Greece and its creditors can advance talks on completing an important review of the country's bailout program

Declining sales force, revenue send Avon shares tumbling

Feb 16, 2017

Avon shares take a tumble after the company reports earnings and revenue that fall short of Wall Street expectations